company background image
0A45 logo

Moderna LSE:0A45 Stock Report

Last Price

US$34.56

Market Cap

US$13.4b

7D

-3.9%

1Y

-66.7%

Updated

16 Mar, 2025

Data

Company Financials +

0A45 Stock Overview

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. More details

0A45 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Moderna, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Moderna
Historical stock prices
Current Share PriceUS$34.56
52 Week HighUS$170.41
52 Week LowUS$28.50
Beta1.86
1 Month Change6.00%
3 Month Change-16.86%
1 Year Change-66.73%
3 Year Change-80.47%
5 Year Changen/a
Change since IPO-40.53%

Recent News & Updates

Recent updates

Shareholder Returns

0A45GB BiotechsGB Market
7D-3.9%-0.4%-0.5%
1Y-66.7%-9.4%8.5%

Return vs Industry: 0A45 underperformed the UK Biotechs industry which returned -9.4% over the past year.

Return vs Market: 0A45 underperformed the UK Market which returned 8.5% over the past year.

Price Volatility

Is 0A45's price volatile compared to industry and market?
0A45 volatility
0A45 Average Weekly Movement10.7%
Biotechs Industry Average Movement7.1%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.1%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0A45's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0A45's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20105,800Stephane Bancelwww.modernatx.com

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
0A45 fundamental statistics
Market capUS$13.38b
Earnings (TTM)-US$3.56b
Revenue (TTM)US$3.24b

4.1x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A45 income statement (TTM)
RevenueUS$3.24b
Cost of RevenueUS$6.01b
Gross Profit-US$2.77b
Other ExpensesUS$790.00m
Earnings-US$3.56b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-9.21
Gross Margin-85.63%
Net Profit Margin-110.04%
Debt/Equity Ratio0%

How did 0A45 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 15:29
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moderna, Inc. is covered by 41 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Ishan MajumdarBaptista Research
Huidong WangBarclays